Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.
Zandberg DP, et al.
Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.
Eur J Cancer. 2019.
PMID: 30576970
Free article.
Clinical Trial.